LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Lung Injury Induced by Crizotinib and Entrectinib in a Patient with ROS1-rearranged Non-small-cell Lung Cancer.

    Nishiyama, Yoshiki / Omori, Shota / Matsumoto, Hiroyuki / Komiya, Kosaku / Hiramatsu, Kazufumi

    Internal medicine (Tokyo, Japan)

    2023  Volume 62, Issue 23, Page(s) 3507–3510

    Abstract: We herein report the first case of c-ros oncogene 1 (ROS1)-rearranged advanced non-small-cell lung cancer (NSCLC) in which lung injury was induced by crizotinib and entrectinib. Crizotinib was administered as first-line chemotherapy in a woman in her ... ...

    Abstract We herein report the first case of c-ros oncogene 1 (ROS1)-rearranged advanced non-small-cell lung cancer (NSCLC) in which lung injury was induced by crizotinib and entrectinib. Crizotinib was administered as first-line chemotherapy in a woman in her early 70s with stage IV NSCLC showing ROS1 rearrangement. This resulted in the development of drug-induced organizing pneumonia, which was alleviated by discontinuing drug administration and giving corticosteroids. Following second-line chemotherapy with entrectinib, a similar lung injury was noted. In cases of crizotinib-induced lung injury, physicians must be alert for drug-induced lung injury in subsequent treatment with entrectinib.
    MeSH term(s) Female ; Humans ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Crizotinib/adverse effects ; Gene Rearrangement ; Lung Injury ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Oncogenes ; Protein Kinase Inhibitors/adverse effects ; Protein-Tyrosine Kinases/genetics ; Proto-Oncogene Proteins/genetics ; Aged
    Chemical Substances Crizotinib (53AH36668S) ; entrectinib (L5ORF0AN1I) ; Protein Kinase Inhibitors ; Protein-Tyrosine Kinases (EC 2.7.10.1) ; Proto-Oncogene Proteins ; ROS1 protein, human (EC 2.7.10.1)
    Language English
    Publishing date 2023-04-14
    Publishing country Japan
    Document type Case Reports ; Journal Article
    ZDB-ID 32371-8
    ISSN 1349-7235 ; 0021-5120 ; 0918-2918
    ISSN (online) 1349-7235
    ISSN 0021-5120 ; 0918-2918
    DOI 10.2169/internalmedicine.1255-22
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Factors Associated with Extended-spectrum β-lactamase-producing Enterobacteria Isolated from Respiratory Samples.

    Matsumoto, Hiroyuki / Komiya, Kosaku / Ichihara, Shogo / Nagaoka, Yuhei / Yamanaka, Marimu / Nishiyama, Yoshiki / Hiramatsu, Kazufumi / Kadota, Jun-Ichi

    Internal medicine (Tokyo, Japan)

    2022  Volume 62, Issue 14, Page(s) 2043–2050

    Abstract: Objective Although extended-spectrum β-lactamase (ESBL)-producing bacteria are a global threat, as they may cause respiratory infection, the factors associated with the isolation of these bacteria from sputum remain unclear. We therefore explored the ... ...

    Abstract Objective Although extended-spectrum β-lactamase (ESBL)-producing bacteria are a global threat, as they may cause respiratory infection, the factors associated with the isolation of these bacteria from sputum remain unclear. We therefore explored the factors related to ESBL-producing Klebsiella pneumoniae and Escherichia coli isolated from sputum samples. Methods This study included consecutive patients admitted to our department from 2010 to 2021 with K. pneumoniae or E. coli isolated from their sputum. The patients were categorized into ESBL-producing and non-ESBL-producing groups, and the factors associated with ESBL-producing bacteria isolation were assessed using a binomial logistic regression analysis. Results We included 82 patients, and ESBL-producing pathogens were isolated from 23 (28%). The usage rates of cephem [odds ratio (OR) 4.000, 95% confidence interval (CI) 1.402-11.409, p=0.010], quinolone (OR 2.961, 95% CI 1.097-7.996, p=0.032), and macrolide (OR 4.273, 95% CI 1.518-12.028, p=0.006) in the past year were significantly higher in the ESBL-producing group than in the non-ESBL-producing group. The multivariate analysis revealed that the applications of cephem (adjusted OR: 4.130, 95% CI: 1.233-13.830, p=0.021) and macrolide (adjusted OR: 6.365, 95% CI: 1.922-21.077, p=0.002) was independently associated with the isolation of ESBL-producing bacteria. Conclusion A history of cephem and macrolide use can be considered a risk factor for ESBL-producing bacteria isolation from sputum samples. Physicians need to consider these risk factors when determining antibiotics for the treatment of patients with respiratory infections.
    MeSH term(s) Humans ; Escherichia coli ; Enterobacteriaceae ; Klebsiella Infections/drug therapy ; beta-Lactamases ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Escherichia coli Infections/drug therapy ; Risk Factors ; Klebsiella pneumoniae ; Bacteria
    Chemical Substances beta-Lactamases (EC 3.5.2.6) ; Anti-Bacterial Agents
    Language English
    Publishing date 2022-12-07
    Publishing country Japan
    Document type Journal Article
    ZDB-ID 32371-8
    ISSN 1349-7235 ; 0021-5120 ; 0918-2918
    ISSN (online) 1349-7235
    ISSN 0021-5120 ; 0918-2918
    DOI 10.2169/internalmedicine.0690-22
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top